Great West Life Assurance Co. Can Holds Position in Tesaro Inc. (TSRO)
Great West Life Assurance Co. Can maintained its position in shares of Tesaro Inc. (NASDAQ:TSRO) during the second quarter, Holdings Channel reports. The institutional investor owned 3,500 shares of the biopharmaceutical company’s stock at the end of the second quarter. Great West Life Assurance Co. Can’s holdings in Tesaro were worth $154,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC purchased a new stake in shares of Tesaro during the second quarter worth approximately $240,000. Societe Generale purchased a new stake in shares of Tesaro during the second quarter worth approximately $286,000. Smith Asset Management Group LP purchased a new stake in shares of Tesaro during the second quarter worth approximately $406,000. Parametrica Management Ltd purchased a new stake in shares of Tesaro during the first quarter worth approximately $251,000. Finally, Legal & General Group Plc raised its stake in shares of Tesaro by 29.9% in the first quarter. Legal & General Group Plc now owns 6,581 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 1,514 shares during the last quarter. 88.81% of the stock is currently owned by institutional investors and hedge funds.
Tesaro Inc. (NASDAQ:TSRO) traded up 2.64% during trading on Wednesday, hitting $107.56. The stock had a trading volume of 1,308,133 shares. The firm’s market cap is $5.52 billion. Tesaro Inc. has a 52-week low of $29.51 and a 52-week high of $108.27. The company has a 50-day moving average of $92.90 and a 200 day moving average of $63.67.
Tesaro (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. The business had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $4.98 million. During the same period last year, the firm earned ($1.51) earnings per share. On average, equities research analysts predict that Tesaro Inc. will post ($7.33) earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on TSRO. Robert W. Baird began coverage on Tesaro in a report on Monday, July 18th. They set an “outperform” rating and a $105.00 price objective for the company. Royal Bank Of Canada began coverage on Tesaro in a report on Friday, August 12th. They set an “outperform” rating and a $122.00 price objective for the company. FBR & Co boosted their price objective on Tesaro from $65.00 to $93.00 and gave the company an “outperform” rating in a report on Wednesday, June 29th. Mizuho restated an “outperform” rating and set a $67.00 price objective on shares of Tesaro in a report on Thursday, June 30th. Finally, Wedbush restated a “buy” rating on shares of Tesaro in a report on Friday, August 5th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Tesaro presently has a consensus rating of “Buy” and a consensus target price of $94.40.
In related news, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $88.54, for a total value of $619,780.00. Following the completion of the sale, the vice president now owns 3,500 shares in the company, valued at $309,890. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total value of $2,509,442.64. Following the completion of the sale, the vice president now owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The disclosure for this sale can be found here. Company insiders own 40.50% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tesaro Inc. (NASDAQ:TSRO).
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.